Back to Retatrutide research
retatrutide gip agonist other 2024-04-10 ClinicalTrials

Retatrutide Phase 3 Trial Shows Strong Potential for Type 2 Diabetes Control

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Background

Type 2 Diabetes (T2D) is a chronic metabolic condition characterized by high blood sugar levels, often leading to severe complications like heart disease, kidney failure, and nerve damage. Despite existing therapies, many individuals with T2D struggle to achieve adequate glycemic control through diet and exercise alone, highlighting a critical need for more effective and comprehensive treatment options. This study specifically addresses the gap in highly effective monotherapy options for T2D patients with inadequate glycemic control.


retatrutide gip agonist glp 1 agonist glucagon agonist protocol relevant
Source: clinicaltrials:NCT06354660 · Ingested 2026-04-03 · Digest: gemini-2.5-flash